

August 2004

# Update Information



## SUBSCRIBER NOTES

### 2004 CD-ROM (1985-current) disc return

**procedures:** It is not necessary to return your monthly outdated (1985-current) Index Record disc to *IDIS*. After you have checked your new monthly (1985-current) Index Record disc, please destroy the previous month's disc. The Article disc is a permanent file, **NEVER DISCARD!** Place the disc at the end of your current article disc file in chronological order for easy access.

***IDIS* WWW Home Page:** Iowa Drug Information Service has a Home Page on the WWW linked to the University of Iowa. Copies of the *World of Drug Information* newsletter, FDA Approval Packages and a form to request a CD-ROM or Web trial can be found here. You can also send us an Internet message directly from our Home Page. The address is: <http://www.uiowa.edu/~idis>

***IDIS* toll-free number:** A toll-free number is available to our U.S. subscribers for questions, comments or inquiries. The number is 1-800-525-4347 (1-800-525-*IDIS*). We encourage you to make use of this number.

**Retrieval Software Sublicense Agreement (RSSA):** It is not necessary for CD-ROM subscribers to sign an RSSA agreement for their 2004 *IDIS* subscription. A copy of the RSSA will be enclosed with each monthly update shipment.

**CD-ROM Retrospective Articles:** The 1997 - 2003 CD-ROM articles are available for purchase. Please check your 2004 Price Sheet for cost information.

## NEW DRUG TERMS

	NUMBER
ALPHA-LACTALBUMIN .....	92000268
BAL-5788 .....	8120673
BMS-310705 .....	10120810
CTL-102 .....	14000803
DRF-1042 .....	10020015
EPO-906 .....	10120809
HEXYL-INSULIN MONOCONJUGATE 2 .....	68200013
KOS-862 .....	10120808
MULBERRY .....	92510187
SHILAJIT .....	92510188
TELAVANCIN .....	8122944
TMC-114 .....	8180809

## CONTINUING EDUCATION ARTICLE

**Article Number 517668:** Cada DJ, Levien T, Baker DE. Ezetimibe. *Hosp Pharm* 2003, 38:357-366. (0.15 CEU)

## FDA APPROVAL PACKAGE

**Article Number 517373-517384:** Anonymous. Annotated Table of Contents. **Abarelix for Injectable Suspension, Plenaxis.** Summary Basis of Approval Equivalent. *FDA Approval Package* 2003.

**Article Number 518043-518053:** Anonymous. Annotated Table of Contents. **Epinastine Ophthalmic Solution, Elestat.** Summary Basis of Approval Equivalent. *FDA Approval Package* 2003.

(continued)

## IDIS COVERAGE OF NEWLY APPROVED DRUGS

### **Apomorphine Hydrochloride Injection, Apokyn®, Bertek**

---

<b>FDA Approval</b>	April 20, 2004, priority review
<b>Indication</b>	Used in adults to treat the acute, intermittent treatment of hypomobility and “off” episodes associated with advanced Parkinson’s disease.
<b>IDIS Database</b>	7 Randomized Controlled Clinical Trials 22 Observational Studies, With Control 29 Observational Studies, No Control 56 Reviews 3 Editorials 20 Letters to Editor 14 Case Reports
<b>IDIS Drug Term</b>	APOMORPHINE 56200001
<b>IDIS Disease Terms</b>	PARKINSON’S DISEASE 332.

### **Azacitidine Injection, Vidaza®, Pharmion**

---

<b>FDA Approval</b>	May 19, 2004, priority review for previous orphan drug
<b>Indication</b>	Used to treat patients with the following:  1) Myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts, refractory anemia with excess blasts.  2) Chronic myelomonocytic leukemia
<b>IDIS Database</b>	2 Randomized Controlled Clinical Trials 21 Observational Studies, With Control 16 Observational Studies, No Control 18 Reviews 2 Editorials 2 Letters to Editor 3 Case Reports
<b>IDIS Drug Term</b>	AZACITIDINE 10080405
<b>IDIS Disease Terms</b>	NEOP, NOS-HEMAPOIESIS/LYMPH 238.7 LEUKEMIA, MYELOID, CHRONIC 205.1